{"filing":{"accession_number":"0001193125-26-338006","cik":"0001813814","ticker":"DFTX","company_name":"Definium Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"dftx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm"},"events":[{"id":25620,"run_id":23253,"accession_number":"0001193125-26-338006","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 6, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated balance sheets and statements of operations. The filing includes detailed financial metrics (R\u0026D expenses of $48.7M, G\u0026A expenses of $26.4M, net loss of $159.0M) and material clinical program updates (positive Phase 3 Emerge results for DT120 ODT in MDD, cash position of $1.1 billion). This is material to investors as it discloses quarterly financial performance and significant clinical milestones for a late-stage biopharmaceutical company.","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26503,"accession_number":"0001193125-26-338006","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 6, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated balance sheets and statements of operations. The filing includes detailed financial metrics (R\u0026D expenses of $48.7M, G\u0026A expenses of $26.4M, net loss of $159.0M) and material clinical program updates (positive Phase 3 Emerge results for DT120 ODT in MDD, cash position of $1.1 billion). This is material to investors as it discloses quarterly financial performance and significant clinical milestones for a late-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:43.394358+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26503,"accession_number":"0001193125-26-338006","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 6, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated balance sheets and statements of operations. The filing includes detailed financial metrics (R\u0026D expenses of $48.7M, G\u0026A expenses of $26.4M, net loss of $159.0M) and material clinical program updates (positive Phase 3 Emerge results for DT120 ODT in MDD, cash position of $1.1 billion). This is material to investors as it discloses quarterly financial performance and significant clinical milestones for a late-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:43.394358+00:00","company_name":"Definium Therapeutics, Inc.","ticker":"DFTX","filing_date":"2026-08-06"}]}